Skip to main content
Aaron Goldberg, MD, Hematology, New York, NY, Memorial Sloan-Kettering Cancer Center

AaronDavidGoldbergMDPhD

Hematology New York, NY

Hematologic Oncology

Assistant Attending Physician

Overview of Dr. Goldberg

Dr. Aaron Goldberg is a hematologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Cornell University Medical College and has been in practice 7 years. He is one of 44 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Hematology.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2014 - 2017
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2011 - 2014
  • Cornell University Medical College
    Cornell University Medical CollegeClass of 2011, MD
  • Rockefeller UniversityPhD, Epigenetics and Chromatin Biology, 2004 - 2010

Certifications & Licensure

  • ME State Medical License
    ME State Medical License 2020 - 2021
  • NC State Medical License
    NC State Medical License 2020 - Present
  • NJ State Medical License
    NJ State Medical License 2018 - 2023
  • MA State Medical License
    MA State Medical License 2014 - 2015
  • NY State Medical License
    NY State Medical License 2014 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASH Fellow Scholar Award in Clinical Research American Society of Hematology, 2018
  • ASCO Young Investigator Award Conquer Cancer Foundation of the American Society of Clinical Oncology, 2017
  • Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Award Pfizer, 2017
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
    Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
    Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
    Aaron D Goldberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Hospital Affiliations